The short version of chain of custody fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
According to the Oxford English Dictionary, the English proper noun "India" derives most immediately from the Classical Latin India, a reference to a loosely-defined historical region of Asia stretching from South Asia to the borders of China. Further etymons are: Hellenistic Greek India (Ἰνδία); Ancient Greek Indos (Ἰνδός), or the River Indus; Achaemenian Old Persian Hinduš (an eastern province of the Achaemenid Empire); and Sanskrit Sindhu, or "river," but specifically the Indus river, and by extension its well-settled basin. The Ancient Greeks referred to South Asians as Indoi, 'the people of the Indus'. The term Bharat (Bhārat; pronounced [ˈbʱaːɾət] ), mentioned in both Indian epic poetry and the Constitution of India, is used in its variations by many Indian languages. A modern rendering of the historical name Bharatavarsha, which applied originally to North India, Bharat gained increased currency from the mid-19th century as a native name for India. Hindustan ([ɦɪndʊˈstaːn] ) is a Middle Persian name for India that became popular by the 13th century, and was used widely since the era of the Mughal Empire. The meaning of Hindustan has varied, referring to a region encompassing the northern Indian subcontinent (present-day northern India and Pakistan) or to India in its near entirety.
=== Alternative treatments === Over 50% of people with MS may use complementary and alternative medicine, although percentages vary depending on how alternative medicine is defined. Regarding the characteristics of users, they are more frequently women, have had MS for a longer time, tend to be more disabled and have lower levels of satisfaction with conventional healthcare. The evidence for the effectiveness for such treatments in most cases is weak or absent. Treatments of unproven benefit used by people with MS include dietary supplementation and regimens, vitamin D, relaxation techniques such as yoga, herbal medicine (including medical cannabis), hyperbaric oxygen therapy, self-infection with hookworms, reflexology, acupuncture, and mindfulness. Evidence suggests vitamin D supplementation, irrespective of the form and dose, provides no benefit for people with MS; this includes for measures such as relapse recurrence, disability, and MRI lesions while effects on health‐related quality of life and fatigue are unclear. There is insufficient evidence supporting high-dose biotin and some evidence for increased disease activity and higher risk of relapse with its use.
=== Multi-photon ionization === In multi-photon ionization (MPI), several photons of energy below the ionization threshold may actually combine their energies to ionize an atom. Resonance-enhanced multiphoton ionization (REMPI) is a form of MPI in which one or more of the photons accesses a bound-bound transition that is resonant in the atom or molecule being ionized.
=== Other uses === Pizotifen has also been reported as highly effective in a severe case of erythromelalgia, a rare neurovascular disease that is sometimes refractory to the other drugs named above. Other applications for which pizotifen may be used include as an antidepressant, or for the treatment of anxiety or social phobia. Animal studies also suggest that pizotyline could be used in the treatment of serotonin syndrome or MDMA overdose in a similar manner to the closely related antihistamine/anti-serotonin medication cyproheptadine. Pizotifen might be useful as a hallucinogen antidote or "trip killer" in blocking the effects of serotonergic psychedelics like psilocybin. It might also be useful in the treatment of MDMA overdose.
=== Statistics === In 2022, the sector with the highest number of companies registered in Denmark is Finance, Insurance, and Real Estate with 204,853 companies followed by Services and Retail Trade with 204,050 and 30,563 companies respectively.
Sources: en.wikipedia.org
It includes the midbrain, pons, and medulla oblongata and regulates essential functions such as breathing, heart rate, and sleep. Brain ventricles A set of interconnected cavities within the brain that produce and circulate cerebrospinal fluid (CSF). Includes the lateral, third, and fourth ventricles. Brain waves Patterns of electrical activity in the brain, typically detected by electroencephalography (EEG). Brain waves are categorized by frequency, such as alpha, beta, delta, and theta waves. Brain-computer interface (BCI) A technology that enables direct communication between the brain and an external device, often used in research, prosthetics, and communication aids for individuals with disabilities. Bradykinesia Slowness of movement, often a symptom of Parkinson’s disease and other disorders involving the basal ganglia. Broca's area A region in the frontal lobe, typically in the left hemisphere, associated with the production of speech. Damage can result in Broca's aphasia, characterized by impaired speech fluency. Broca's aphasia A language disorder caused by damage to Broca's area, resulting in slow, laborious speech with relatively preserved comprehension. Brodmann areas Regions of the cerebral cortex defined by Korbinian Brodmann based on cytoarchitecture. These areas are still widely used to describe functional brain localization (e.g., Brodmann area 17 = primary visual cortex). Burst firing A pattern of rapid spikes from a neuron followed by a period of quiescence. It plays a role in sensory encoding and signal amplification in various brain circuits.
== W == Johannes Diderik van der Waals (1837–1923), Dutch physicist Sir James Walker (1863–1935), Scottish physical chemist John E. Walker (born 1941), British chemist, 1997 Nobel Prize in Chemistry Otto Wallach (1847–1931), German chemist, 1910 Nobel Prize in Chemistry John Warner (born 1962), American chemist, 2014 Perkin Medal, one of the "founders" of green chemistry Alfred Werner (1866–1919), Swiss chemist, 1913 Nobel Prize in Chemistry Thomas Summers West (1927–2010), British analytical chemist Peter Jaffrey Wheatley (1921–1997), English chemist Chaim Weizmann (1874–1952), Russian chemist, developed the ABE-process George M. Whitesides (born 1939), American chemist John Rex Whinfield (1901–1966), British chemist, discovered polyester fibres Otto Wichterle (1913–1998), Czech chemist, known for inventing modern contact lenses Heinrich Otto Wieland (1877–1957), German chemist 1927 Nobel Prize in Chemistry Julius Wilbrand (1839–1906), German chemist, inventor of TNT Harvey W.
Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to encourage healthy behaviors that can decrease the negative consequences for those facing life challenges like homelessness and food insecurity, or engaging in harm-prone behaviors such as recreational drug use and sexual activity. Harm reduction initiatives recognize that people can make positive changes to protect themselves and others, without requiring abstinence. Harm reduction is most commonly applied to approaches that reduce adverse consequences from drug use, and harm reduction programs now operate across a range of services and in different regions of the world. As of 2020, some 86 countries had one or more programs using a harm reduction approach to substance use, primarily aimed at reducing blood-borne infections resulting from use of contaminated injecting equipment. Needle-exchange programmes, or syringe service programmes, reduce the likelihood of people who use heroin and other substances sharing the syringes and using them more than once. Syringe-sharing often leads to the spread of infections such as HIV or hepatitis C, which can easily spread from person to person through the reuse of syringes contaminated with infected blood. Needle and syringe programmes (NSP) and Opioid Agonist Therapy (OAT) outlets in some settings offer basic primary health care.
==== Absorption ==== Pseudoephedrine is orally active and is readily absorbed from the gastrointestinal tract. Its oral bioavailability is approximately 100%. The drug reaches peak concentrations after 1 to 4 hours (mean 1.9 hours) in the case of the immediate-release formulation and after 2 to 6 hours in the case of the extended-release formulation. The onset of action of pseudoephedrine is 30 minutes.
Sources: en.wikipedia.org
== Pharmacokinetics == Chlordiazepoxide is a long-acting benzodiazepine drug. The half-life of chlordiazepoxide is from 5 to 30 hours but has an active benzodiazepine metabolite, nordiazepam, which has a half-life of 36 to 200 hours. The half-life of chlordiazepoxide increases significantly in the elderly, which may result in prolonged action as well as accumulation of the drug during repeated administration. Delayed body clearance of the long half-life active metabolite also occurs in those over 60 years of age, which further prolongs the effects of the drugs with additional accumulation after repeated dosing. Despite its name, chlordiazepoxide is not an epoxide.
== External links == "Glucagon Receptor Family: GLP-1". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-10-25. glucagon-like+peptide+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P43220 (Glucagon-like peptide 1 receptor) at the PDBe-KB.
Substitution reactions that proceed through a free carbocation intermediate, such as unimolecular substitution reactions, lead to non-stereospecific addition of substituents which results in racemization. Although unimolecular elimination reactions also proceed through a carbocation, they do not result in a chiral center. They result instead in a set of geometric isomers in which trans/cis (E/Z) forms are produced, rather than racemates. In a unimolecular aliphatic electrophilic substitution reaction, if the carbanion is planar or if it cannot maintain a pyramidal structure, then racemization should occur, though not always. In a radical-substitution reaction, if the formation of the free radical takes place at a chiral carbon, then racemization is almost always observed. The rate of racemization (from L-forms to a mixture of L-forms and D-forms) is used as a way of dating biological samples in tissues with slow rates of turnover, forensic samples, and fossils in geological deposits. This technique is known as amino acid dating.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.